Assessing the preferences of patients with psoriasis. A quantitative, utility approach

Zug, K. A.

doi:10.1001/archderm.131.5.561

Cited by 40 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SG involves patients making a choice based on uncertainty, whereas the EQ-VAS does not. Consistent with previous studies, we found a low correlation between SG and the EQ-VAS [42][43][44][45]. The correlations between the EQ-VAS and other HRQoL instrument scores were all considerably higher than the correlations with SG.…”

Section: Validitysupporting

confidence: 91%

Validity of standard gamble utilities in patients referred for aortic valve replacement

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Validitysupporting

confidence: 91%

Validity of standard gamble utilities in patients referred for aortic valve replacement

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Serono had no primary sources of utility data for this purpose (for example, from trials). Instead, a literature search identified a study by Zug and colleagues 26 which elicited utilities, based on the time trade-off instrument, from 87 patients with psoriasis. Serono argues that non-response in their model can appropriately be given a utility value that accords with Zug and …”

Section: Methodsmentioning

confidence: 99%

“…25 However, a US study of 87 patients at a tertiary medical clinic, in which three QoL instruments were assessed, found no relationship between HRQoL and any demographic variable, including age, gender and education. 26 The economic impact of psoriasis in terms of outof-pocket expenses increases with severity 27 and the effect is greater in lower income groups. 23 A UK study of people with severe psoriasis found that around 60% had taken time off work in the previous year as a direct result of their condition.…”

Section: Significance In Terms Of Ill-healthmentioning

confidence: 99%

Etanercept and efalizumab for the treatment of psoriasis: a systematic review

Woolacott¹,

Hawkins²,

Mason³

et al. 2006

Health Technol Assess

140

159

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

“…18 Treatment preferences of patients with psoriasis have been investigated in a number of studies using time trade-off, willingness-to-pay, and standard gamble methods, as well as visual analogue scales. [19][20][21][22] Another approach to assess preferences is conjoint analyses in which participants have to choose between treatment options, resembling actual decision-making. [23][24][25] Conjoint analysis exercises force trade-offs in a choice context and allow quantification and comparison of attributes related to treatment outcomes and processes.…”

Section: Introductionmentioning

confidence: 99%

Comorbidities significantly impact patients’ preferences for psoriasis treatments

Schmieder

Schaarschmidt

Umar

et al. 2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Assessing the preferences of patients with psoriasis. A quantitative, utility approach

Cited by 40 publications

References 0 publications

Validity of standard gamble utilities in patients referred for aortic valve replacement

Validity of standard gamble utilities in patients referred for aortic valve replacement

Etanercept and efalizumab for the treatment of psoriasis: a systematic review

Comorbidities significantly impact patients’ preferences for psoriasis treatments

Contact Info

Product

Resources

About